



For Immediate Release

STEVEN HUBERT JOINS OMNIA BIOLOGICS

(March 15, 2011 – Rockville, MD) Biologics development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that Steven Hubert has joined the Omnia team as Vice-President of Operations.

Over the course of his 22-year career, he has held positions of increasing responsibility in the development and manufacturing of pioneering biologic products including recombinant protein therapeutics and vaccines, monoclonal antibodies, gene therapy vectors, and live attenuated bacterial vaccines. He has held senior scientific, engineering, and management positions in organizations like Genetic Therapy, Inc., Human Genome Sciences, Inc., and the Aeras Global Tuberculosis Vaccine Foundation. He contributed to the development of products approved for use in the European Union and the United States including HumaSPECT®, the first fully human monoclonal antibody agent for diagnosing and imaging cancer throughout the body, BENLYSTA® (belimumab) which has been successfully licensed in systemic lupus, and ABthrax® (raxibacumab) which has been purchased for the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalation anthrax.

“Steven has worked for some of the most innovative enterprises in the life sciences successfully creating commercial value from ideas. He brings a wealth of knowledge to efficiently translate scientific discoveries into clinical products.” Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc. commented. “He is a highly valuable resource for our clients to effectively move their products forward in the clinic.”

Mr. Hubert has a bachelor’s degree in Biology from VA Tech. and a Masters Degree in Biotechnology from the Johns Hopkins University.

About Omnia Biologics: (www.omniabiologics.com)

Omnia offers translational medicine services in the areas of process development, assay development, GMP manufacture, and fill-finish for preclinical and clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.

###

CONTACT:

Sami Cardak Omnia Biologics, Inc. 12111 Parklawn Drive, Rockville, Maryland, 20852, USA,
E-mail: info@omniabio.com, Tel: 301-984-5928, Fax 301-984-2515.